Skip to main content

Table 2 Patient Treatment Satisfaction Scores With Fremanezumab on the Likert Scalea,b,c

From: Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

Efficacy dimension, mean (SD) Overall (n = 253) EM (n = 119) CM (n = 134) Monthly (n = 122) Quarterly (n = 131)
Ability to prevent or treat migraine 6.1 (1.4) 6.5 (0.9) 5.8 (1.6) 6.2 (1.5) 6.1 (1.3)
Way the medication relieved symptoms 6.1 (1.4) 6.4 (1.1) 5.8 (1.6) 6.1 (1.5) 6.1 (1.3)
Time it took to start working 5.7 (1.4) 5.9 (1.3) 5.5 (1.5) 5.7 (1.5) 5.7 (1.4)
Ease of medication administration 6.0 (1.4) 6.1 (1.3) 5.9 (1.4) 6.1 (1.2) 5.9 (1.5)
  1. CM, chronic migraine; EM, episodic migraine
  2. aFor ability to prevent or treat migraine, way the medication relieved symptoms, and time it took to start working, patients responded to the following questions: “How satisfied or dissatisfied were you with…”
  3. • “…the ability of the clinical trial medication to prevent or treat your migraine?”
  4. • “…the amount of time it took the clinical trial medication to start working?”
  5. • “…the way the clinical trial medication relieved your migraine symptoms?”
  6. bFor ease of medication administration, patients responded to the following question: “How easy or difficult was it to have the clinical trial medication administered in the clinical trial site (doctor’s office)?”
  7. cThe Likert Scale ranged from: 1 = “extremely dissatisfied” to 7 = “extremely satisfied”; or 1 = “extremely difficult” to 7 = “extremely easy” (for ease of medication administration question only)